

For reauthorization :

1. Zulresso will not be authorized for continuous administration (it is a single time injection).

CareSource considers Zulresso (brexanolone) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off -Label policy.

DATE	ACTION/DESCRIPTION
08/12/2019	New policy for Zulresso created.
05/26/2022	Transferred to new template. Updated references. Added site of service and J code. Expanded the type of baseline depression scale acceptable for diagnosis.